drugset / Trial / NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Phase 2
Not yet recruiting
32 enrolled
Haibo Shao
First Hospital of China Medical University · collabHarbin Medical University Third Affiliated Hospital · collabLiaoning Cancer Hospital & Institute · collabThe Affiliated Hospital of Yanbian University · collabThe General Hospital of Northern Theater Command · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Timeline
- Start
- 2026-06
- Primary completion
- 2029-02
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epalrestat | Small molecule | 50 mg | — |
| Background | Donafenib | Small molecule | 0.2 g | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |